Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

NCT04194034 | Terminated Phase 1 DMC

• 1 other identifier: TG6002.03
• Study Type: interventional
• Target: 15
• Locations: 2 countries
• Sites: 3

Brief Summary

This study will include two parts:

• Phase I part is a dose-escalation study to assess the safety of increasing doses of TG6002 in combination with oral flucytosine (5-FC) in consecutive cohorts of 3 to 6 patients with colorectal cancer and unresectable liver metastases according to a 3+3 design
• Phase IIa part is an extension of the phase I part at the recommended phase II dose to evaluate the efficacy of TG6002 in combination with oral flucytosine (5-FC) in patients with colorectal cancer and unresectable liver metastases. In both parts, tumor response will be evaluated on local assessment using RECIST 1.1. All patients will be followed until disease progression, death due to any cause or the date of data cut-off, whichever occurs first.

Conditions

Colorectal Neoplasms

Outcome Measures

Primary Outcomes (2)

• Dose-limiting toxicities (Phase I part)

  Incidence of Adverse events using CTCAE v5.0

  Day 28

• Disease Control Rate (Phase II part)

  Proportion of patients whose tumour assessment is either complete response (CR), partial response (PR), or stable disease (SD)

  Week 10

Study Arms (1)

TG6002 and flucytosine (5-FC) combination

EXPERIMENTAL

Biological: TG6002; Drug: Flucytosine (5-FC)

Interventions

TG6002 BIOLOGICAL

Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D). Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment. A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient.

TG6002 and flucytosine (5-FC) combination

Flucytosine (5-FC) DRUG

Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination. A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between.

TG6002 and flucytosine (5-FC) combination

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Unresectable metastatic CRC with at least one measurable liver metastasis
• At least one liver metastasis amenable to biopsy
• Patients previously exposed to fluoropyrimidine-based chemotherapy
• (Phase I) Patients having failed, are intolerant to, or unsuitable for both oxaliplatin and irinotecan-based chemotherapy, or, in the UK only, patients on or entering a period of clinical observation without treatment
• (Phase IIa) Patients having failed, are intolerant to, or unsuitable for both oxaliplatin and irinotecan-based chemotherapy.
• Aged ≥18 years
• Estimated life expectancy \>3 months
• ECOG performance status ≤1

You may not qualify if:

• Predominant extrahepatic disease
• Symptomatic brain metastases or meningeal tumors
• Any contraindication to intrahepatic artery infusion procedure
• Received other investigational therapy or had surgery within 4 weeks of treatment initiation which would interfere with study treatment
• Received locoregional therapy for CRC within 4 weeks prior to treatment initiation
• Severe uncontrolled coagulopathy OR anticoagulant medication
• Antiviral therapy active on vaccinia virus, e.g., ribavirin, interferon/pegylated interferon
• Immunosuppression due to immunosuppressive medication including steroids equivalent to prednisolone \>10mg/day taken for more than 4 weeks within 3 months prior to TG6002 treatment initiation
• Patients treated with 3 or more anti-hypertensive agents AND/OR patients with signs of advanced hypertensive disease, such as left ventricular hypertrophy, hypertensive encephalitis or history of hemorrhagic stroke.

Sponsors & Collaborators

• Transgene: lead

Study Sites (3)

Centre Léon Bérard

Lyon, 69008, France

Location

Institut Gustave Roussy

Villejuif, 94800, France

Location

NHS St James's University Hospital

Leeds, LS9 7TF, United Kingdom

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

Flucytosine

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Cytosine; Pyrimidinones; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 8, 2019
• First Posted: December 11, 2019
• Study Start: January 17, 2020
• Primary Completion: February 23, 2023
• Study Completion: February 23, 2023
• Last Updated: June 23, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1); FR (2)